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Abstract 
Objective. - Over the last decade, the Cambridge Neuropsychological Test Automated Battery (CANTAB), 
which comprises visuo-spatial tasks, has been utilized in cognitive studies of schizophrenia. A clear approach 
concerning the usage of CANTAB for the appraisal of neuro-cognitive dysfunction in schizophrenia is currently 
lacking. 
Method. - In this paper, we have first reviewed the overall applications of CANTAB and then evaluated 
methodological strengths and weaknesses of CANTAB as a neurocognitive battery for schizophrenia. We carried 
out a systematic search and assessment of studies where CANTAB was utilized to measure cognitive function in 
schizophrenia. We have also attempted to quantify the available data and perform a meta-analysis, but this 
approach turned out to be still premature. 
Results. - CANTAB has enabled researchers to highlight significant deficits affecting broad cognitive domains in 
schizophrenia, such as working memory, decision-making, attention, executive functions and visual memory. So 
far, the most consistent deficit observed with CANTAB testing has been attentional set-shifting, suggestive of 
fronto-striatal dysfunctions. In addition, preliminary evidence points towards the potential use of CANTAB to 
identify cognitive predictors of psychosocial functioning, to describe the relationships between symptoms and 
cognition, and to measure the impact of pharmacological agents on cognitive functioning. 
Conclusion. - CANTAB has been used successfully to highlight the range of visuo-spatial cognitive deficits in 
schizophrenia, producing similar results to those obtained with some traditional neuropsychological tests. 
Further studies validating the use of CANTAB following the standard set by Measurement And Treatment 
Research to Improve Cognition in Schizophrenia (MATRICS) are warranted. 
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1. Introduction 
Over the last decade, the Cambridge Neuropsychological Test Automated Battery  (CANTAB)  has been utilized 
in cognitive studies of schizophrenia. The CANTAB was originally written and developed at the University of 
Cambridge by Barbara Sahakian, Trevor Robbins and colleagues in 1986. It consists of a series of interrelated 
computerized non-verbal tests of memory, attention, and executive function. At the present time CANTAB 
consists of 19 visuo-spatial tests (CANTAB eclipse version 2.0). The tests are: Affective Go/ No-go (AGN); 
Big/Little Circle (BLC); Cambridge Gambling Task (CGT); Choice Reaction Time (CRT); Delayed Matching to 
Sample (DMS); Intra-Extra Dimensional Set Shifting (IED); Graded Naming Test (GNT); Matching to Sample 
Visual Search (MTS); Motor Screening (MOT); Paired Associated Learning (PAL); Pattern Recognition 
Memory (PRM); Rapid Image Visual Processing (RVP); Reaction Time (RTI); Spatial Recognition Memory 
(SRM); Spatial Span (SSP); Spatial Working Memory (SWM); Stocking of Cambridge (SOC); Simple Reaction 
Time (SRT); Verbal Recognition Memory (VRM). For more details, see Table 1 and 
http://www.cantab.com/cantab/site/home.acds. IED, SOC, SSP and RVP tests are respectively close versions of 
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the Wisconsin Card Sorting Test [8], the Tower of London [60], the Corsi's Block Tapping Task (CBT) [36] and 
the Continuous Performance Test (CPT) [56]. 
In this review, we first discuss the methodological strengths and weaknesses of CANTAB as a neurocognitive 
battery. Then, we evaluate various applications of CANTAB in schizophrenia, which has been utilized to 
highlight cognitive deficits in schizophrenia (compared to healthy controls and other patient populations), to 
identify cognitive predictors of the disease, to identify cognitive predictors of psychosocial functioning, to divide 
schizophrenia into subgroups with enhanced phenotypic homogeneity, to describe the relationships between 
cognitive and occulomotor deficits in schizophrenia and to measure the impact of pharmacological agents on 
cognition (Table 2). 
 
Table 1 Scales description 
AGN Affective Go/No-go Information processing biases for positive and negative stimuli → mean 
correct latency/total commissions/ total omissions. Not language free 
BLC Big/Little Circle Comprehension and learning reversal → percent correct/total 
correct/total attempts/total errors/mean correct latency 
CGT Cambridge Gambling Task Impulse control and risk-taking in decision making → quality of 
decision making/deliberation time/risk taking/risk adjustment/delay 
aversion/overall proportion bet 
CRT Choice Reaction Time Speed of choice response → latency/correct responses/incorrect 
responses/omissions/commissions 
DMS Delayed Matching to Sample Simultaneous and delayed perceptual matching → numbers and 
percentage correct/latency/statistical analysis 
GNT Graded Naming Test Lexical/semantic memory by assessing object-naming ability → total 
correct/total errors/totals attempts/ percent correct/normative Z-
score/normative percentile 
IED Intra-Extra Dimensional Set 
Shifting 
Rule acquisition and attentional set-shifting → errors/original 
focus/numbers of trials and stage completed 




Matching to Sample Visual 
Research 
Ability to match visual samples, reaction time and movement time → 
correct numbers/correct percentages/ latency 
PAL Paired Associates Learning Episodic visuo-spatial memory, learning and association ability → 
errors/trials/stages completed/memory scores 
PRM Pattern Recognition Memory Recognition memory for patterns → numbers and percentages correct 
and incorrect/latency 
RTI Reaction Time Speed of response → reaction time/movement time 
RVP Rapid Visual Information 
Processing 
Sustained visual attention → hits, misses, false alarm and 
rejections/probabilities and sensitivity calculated using SDT/latency 
SOC Stockings of Cambridge Spatial planning and motor control → problem solved in minimum 
moves/initial thinking time for 2, 3, 4, and 5-move problems/subsequent 
thinking time for 2, 3, 4, and 5-move problems/mean moves for 2, 3, 4, 
and 5-move problems. NTOL: adaptation of the previous task with 
reducing the motors demands placed on subject 
SRM Spatial Recognition Memory Recognition memory for spatial locations → number correct/percent 
correct/mean correct latency 
SRT Simple Reaction Time Speed of response to a single stimulus → correct 
responses/commissions/omissions/latency 
SSP Spatial Span Working memory capacity → span length/errors 
SWM Spatial Working Memory Working visuo-spatial memory and strategy use → errors (between, 
within, double and total)/strategy score 
VRM Verbal Recognition Memory Immediate free recall, and immediate and delayed recognition memory 
→ free recall: total correct, total novel words, total 
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Table 2 Study demographics 
Study 
references 
Test items Drug Tx. N Subjects diagnosis 
[1,2] SSP, DMS, SWM, IED, SOC Medicated 47 Paranoid 
[3] SSP, SWM, SOC Medicated 24 Schizophrenia/inpatient 
[5] PRM, SRM, SOC, IED Mixed 53 First-episode 
[6] SSP, PRM, SOC, SWM Medicated 152 First-episode 
[7] MOT, BLC, SWM, RTI, SSP, PRM, SRM, RVP, 
PAL, IED, MTS, DMS, SOC 
Mixed 11 Pre-psychotic 
[26] SOC, SWM, SSP, IED, PRM, SRM Medicated 136 First-episode 
[27] SSP, PRM, SWM, SOC, IED Medicated 93 First-episode 
[16] IED, DMS, PRM, SRM, PAL, SSP, SWM NA 28 Elder schizophrenia 
[30] SSP Medicated 40 Chronic 
[33] DMS Medicated 105 First-
episode/schizophreniform/ 
schizophrenia 
[35] SOC, SRT, CRT Medicated 27 Schizophrenia 
[43] MOT, SWM, SOC, SSP Medicated 36 Chronic/inpatient 
[42] IED Medicated 24 Chronic/inpatient 
[44] SSP, SWM, PRM, SRM, DMS Medicated 54 Chronic/inpatient 
[45] PAL, MOT Medicated 76 DD/outpatient 
[48] SOC, RTI, PAL, MOT Medicated 88 Outpatient 
[50] SOC, RVP, RTI, PAL, MOT Medicated 73 Outpatient 
[49] MOT, PAL, RTI, SOC, RVP Medicated 55 Outpatient 
[10] IED, PRM, SRM Medicated 32 Chronic 
[11] PRM, SRM, DMS, SSP, SWM, SOC, IED, NTOL Medicated 12 Chronic 
[52] MOT, RTI, MTS, DMS, PRM, SRM, PAL, SSP, 
RVP, SWM, IED, SOC 
Medicated 55 Schizophrenia/schizo-
affective out/inpatient 
[25] SSP, PRM, SRM, SWM, SOC, IED Mixed 30 First-episode 
[22] SWM, SSP, PRM, SRM Mixed 63 First-episode 
[24] CGT Medicated 50 First-episode/chronic 
[21] SSP, PRM, SWM, SOC, IED Medicated 109 First-episode 
[62] SOC, MOT, PAL, RTI Medicated 57 Schizophrenia/schizo-
affective outpatient 
[64] MOT, PRM, DMS, SWM, SSP, NTOL, IED Medicated 20 Chronic 
[66] IED, SOC Medicated 28 Out/inpatient 
[65] PRM, SRM, SSP, SWM Medicated 28 Out/inpatient 
[67] SSP, SWM, DMS NA 38 High risk 
NA, not available; DD, Dual Diagnosis. 
 
2. CANTAB defined 
The development of the CANTAB was heavily guided by a number of existing neuropsychological paradigms 
commonly used to assess cognitive dysfunction in non-human primates with selective neurochemical or 
neuroanatomical lesions. The developers adapted experimental tasks with longstanding traditions of brain-to-
behavior assessment into a format that could be readily accessed by human participant with neurological or 
psychiatric disorders, or both [15]. However, as the battery was developed, tests based on methodological 
advances in neuropsychological assessment of human patients were also added, for example, a DMS procedure 
analogous to the one used by Gaffan [17] and Mishkin [37] to determine the neural basis of visual recognition 
memory in infrahuman primates [61]. Individual tasks have been extensively studied in order to define and 
validate their neural correlates, particularly with the goal of dissociating the performance of humans with frontal 
versus temporal lobe neuropathology [38-40,54] and to distinguish patterns of cognitive deficits in temporal 
versus frontal-lobe dementias [28,58,59]. Robbins and collaborators [53] have administered the CANTAB 
battery to a large group of elderly volunteers in the age range of 55-80 years and showed that scores on 
CANTAB subtests fall into readily separable factors which can plausibly be identified with particular groups of 
cognitive functions that are known to be supported by distinct neural subsystems. For example, the SWM is 
especially dependent upon intact frontal lobes, in contrast to the PRM which is unaffected by frontal damage but 
is sensitive to lesions of the temporal lobe [40]. In a positron emission tomography (PET) scanning study, Baker 
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and colleagues [4] found that for the SOC, a task analogue to the Tower of London test [60], there is widespread 
activation of the parietal and occipital cortices, and other distinct areas of the frontal lobe, including the anterior 
cingulate cortex which is associated with task difficulty. Most importantly, they have demonstrated no 
differential temporal lobe activation, confirming the fact that this task implicates neural pathways distinct from 
the DMS, which only involves the temporal lobe, but not the frontal cortex and its associated frontostriatal loops 
[4]. 
CANTAB has been standardized on a large population aged between 4 and 90 years old in various research 
studies [63], and its validity has been established in a wide variety of clinical populations [15], including 
neurodegenerative diseases, neurosurgical cases, psychiatric disorders, and acquired pathology. Some of the 
specific disorders include: Alzheimer's disease [58,59], dementia of the frontal type [57], Parkinson's disease 
(PD) [58], Huntington's disease [20], frontal, temporal lobe and amygdalo-hippocampectomy [40], and unipolar 
depression [12]. Neurological validation may enable specific neurobiological hypotheses to be addressed. 
Furthermore, these tests have been shown to possess acceptable to high levels of concurrent validity and test-
retest reliability [14]. 
2.1. Strengths and weaknesses of CANTAB 
CANTAB has advantages and some disadvantages, mostly related to its practical application and methodological 
concerns, which are described in Table 3. 
Table 3 Strengths and weaknesses 
Strengths  
1 Standardized testing procedure Includes standardized feedback and detailed recording of data 
2 User-friendly quality Touch screen monitor 
Can continuously be checked to ensure that task demands are 
correctly understood and 
levels of difficulty can continuously be adjusted 
Playful, attractive interface and game-like quality 
3 Can be administered by a non-
neuropsychologist 
Nonetheless, basic knowledge in neuropsychological assessment 
is required 
4 Non-verbal nature Largely language-independent and culture-free, permitting multi-
centre studies 
5 Flexible batteries Allows selecting tasks specific to research or clinical interests, 
using clinical or parallel 
versions of the test 
Parallel version of the task permit for testing in repeated measure 
designs [64] 
6 Graded nature Reduces the likelihood of floor and ceilings effects 
Weaknesses  
1 Relatively expensive Purchasing a touch screen monitor 
2 Mainly visuo-spatial cognitive functions Limits conclusions about patient's verbal functioning 
Exceptions are: Verbal Recognition Memory (VRM) and Graded 
Naming Test (GNT) 
3 Lack of comparison to traditional 
neuropsychological tests 
Difficult to produce an interpretation of results in line with 
traditional neuropsychological concepts, models and theories 
4 Questionable test/re-test reliability and 
practice effects 
Lowe and Rabbit [31] have evaluated test/re-test correlations and 
practice effects for CANTAB from large groups of healthy 
elderly and found many of the CANTAB measures have poor 
test-retest reliability and modest practice effects 
 
Table 4 Frequencies in subscale usage 
Scales Name Frequency (%) Study references 
CGT Cambridge Gambling Task 1/31 (3.23) [24] 
CRT Choice Reaction Time 1/31 (3.23) [35] 
DMS Delayed Matching to Sample 10/31 (32.26) [1,2,7,11,16,33,44,52,64,67] 
IED Intra/extra-Dimensional Set Shifting 14/31 (43.16) [1,5,7,10,11,16,21,25-27,42,52,64,66] 
MOT Motor Screening 8/31 (25.8) [7,43,46,49,50,52,62,64] 
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MTS Matching to Sample Visual Search 2/31 (6.45) [7,52] 
OTS One Touch 
Stockings of Cambridge 
2/31 (6.45) [11,64] 
PAL Paired Associates Learning 8/31 (25.8) [7,16,46,48-50,52,62] 
PRM Pattern Recognition Memory 14/31 (43.16) [5,7,10,11,16,21,22,25-27,30,44,52,64] 
RTI Reaction Time 6/31 (19.35) [7,48-50,52,62] 
RVP Rapid Visual Processing 4/31 (12.9) [7,48,49,52] 
SOC Stockings of Cambridge 17/31 (54.84) [1,3,5-7,11,21,25-27,35,48-50,52,62,66] 
SRM Spatial Recognition Memory 12/31 (38.7) [5,10,11,16,21,22,25,30,44,52,64,65] 
SRT Simple Reaction Time 1/31 (3.23) [35] 
SSP Spatial Span 17/31 (54.84) [1,3,6,7,11,16,22,23,26,27,43,44,52,64,6
5,67] 
SWM Spatial Working Memory 16/31 (51.61) [1,3,6,7,11,16,21,22,25-
27,43,52,64,65,67] 
 
3. CANTAB in schizophrenia 
3.1. Cognitive deficits in schizophrenia 
The tests of CANTAB used in studies of schizophrenia have allowed examination of cognitive functions such as 
attention, memory and executive functions, characterizing the nature of the impairment and the association with 
focal brain regions. After a compilation of all the studies investigating cognition in schizophrenia using 
CANTAB, we have tabulated a frequency table of the tasks utilized to date (Table 4). The most frequent tasks 
were as follow: SOC (13 studies); SWM (10 studies); PRM (10 studies), SRM (10 studies); IED (11 studies). 
This literature has highlighted broad cognitive deficits in schizophrenia, involving short-term memory, long-term 
memory, attention, and executive functions. 
3.2. Schizophrenia patients 
Elliott et al. [10] compared the performance of patients suffering from schizophrenia to controls on the IED task. 
This task provides a componential analysis of the Wisconsin Card Sorting Test (conditions termed 'perseveration' 
and 'learned irrelevance') and it was earlier revealed to be sensitive to frontal lobe dysfunction and PD. 
Medicated chronic schizophrenia patients proved to be significantly impaired on the perseveration but not the 
learned irrelevance condition. This result points to specific deficits in set-shifting ability of executive function in 
schizophrenia. Tyson et al. [66] investigated executive functions involving attentional set-shifting tested with 
IED and planning abilities tested with SOC in schizophrenia patients. They found that on both tests, patients 
performed poorer than controls. The authors also tested whether these deficits are stable during the course of the 
illness (trait deficits) or if they fluctuate along symptom changes (state deficits). They observed no change in 
cognitive performance during the 9-month follow-up, a result consistent with the hypothesis that executive 
dysfunctions in schizophrenia are stable over time. Almeida et al. [1] investigated cognitive functioning in 
psychotic states arising in late life (late paraphrenia) using the IED, SWM and SOC tasks. Compared to controls, 
patients showed deficits in all tasks. Based on these findings, the authors proposed that late paraphrenia is linked 
with a decline in measures of universal abilities and executive skills, instead of a distinctive pattern of cognitive 
impairments. Tyson et al. [65] investigated memory deficits in a schizophrenia group with a wide range of illness 
length (3 weeks to 38 years), using the PRM, SSP and SWM tasks. They showed that patients with schizophrenia 
have deficits in all aspects of memory measured with CANTAB, and that these deficits remain stable over time 
(at least over 18 months). The above studies highlight broad cognitive deficits in schizophrenia, especially 
deficits on the IED task. 
3.3. First-episode schizophrenia patients 
Hutton and Huddy [21] studied cognitive functioning in first-episode schizophrenia patients, using the SSP, 
PRM, SWM, SOC and IED tasks. They observed deficits on all these tasks in patients, relative to controls. Joyce 
et al. [26] investigated executive functions in first-episode schizophrenia patients and found that SWM was 
impaired in patients because of inadequate strategy use. Patients also showed reduced planning time and 
suboptimal problem-solving ability when tested with SOC. However, it must be considered that Hutton et al. 
[25] were not able to replicate the finding of an impaired performance of first-episode schizophrenic patients on 
the IED task, as shown by Tyson et al. [66], Almeida et al. [1], Hutton and Huddy [21], and Elliott et al. [10]. 
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Examining executive function (planning and strategy) in first-episode patients with tests known to be sensitive to 
frontal lobe function (e.g. SOC, SWM, and IED), Hutton et al. [25] showed that patients suffering from 
schizophrenia have profound executive impairments, but not in the attentional set-shifting abilities, which were 
generally unimpaired. 
Employing the DMS task in first-episode schizophreniform disorder and established schizophrenia, Mathes et al. 
[33] have disentangled impairments of working memory subprocesses. A deficit was found in both patient 
groups in the processes essential to actively maintain information. 
Using a task sensitive to orbitofrontal dysfunction, the newly developed CGT, Hutton et al. [24] measured 
decision making in first-episode and chronic schizophrenia patients. The deficits highlighted using this task were 
more prominent in the chronic patients, relative to the first-episode patients. This finding further adds to the 
already growing evidence of orbitofrontal dysfunction in schizophrenia, and advises that the evolution of the 
disease or long duration of treatment with antipsychotics may actually sway performance on this task. 
3.4. Subtyping schizophrenia's cognitive profiles 
Considering the symptomatic heterogeneity of schizophrenia, important efforts have been invested in providing a 
more refined description of the phenotypic features of the pathology, using experimental procedures, including 
neuropsychological tests [27]. From that perspective, CANTAB tasks have been recently used to divide 
schizophrenia patients into distinctive subgroups according to cognitive profiles, both empirically and clinically 
useful. 
A study by Almeida et al. [2] has explored the heterogeneity of late paraphrenia, using the DMS, IED, SSP, and 
SWM tasks. The authors performed a factor analysis which produced a division of paranoid psychosis into two 
patient clusters: type A, which corresponds to patients with a wide range of psychotic symptoms, mild 
neurological signs, and cognitive deficits restricted to executive functions; and type B, which includes patients 
with less complex psychotic symptoms associated with marked neurological signs and generalized cognitive 
impairments. 
Joyce et al. [27] with utilization of SSP, PRM, SWM, SOC, and IED tasks in first-episode schizophrenia 
patients, determined cognitive heterogeneity in chronic schizophrenia to be also present at illness onset. They 
have found that patients who demonstrated preserved IQ in the normal range achieved similar scores to the 
controls, whereas other patients showed a decline in neuropsychological function. On the contrary, impairment 
of the spatial working memory was seen as a common feature in all patients. 
Potvin et al. [45] used the MOT and PAL tasks to compare the cognitive performance of schizophrenia patients 
with and without a substance use disorder (SUD), since the lifetime prevalence of SUD is close to 50% in 
schizophrenia [51]. The authors found that dual diagnosis patients showed a better performance. They concluded 
that their finding suggests either that substance abuse relieves the cognitive deficits of schizophrenia or that the 
patients with less cognitive deficits are more prone to substance abuse. However, Barnes et al. [6] also compared 
the cognitive functioning of single and dual diagnosis patients, using CANTAB tasks (PRM, SOC, SSP, and 
SWM) and found no significant differences between the two groups. 
In a two-year longitudinal study, Stip et al. [62] used CANTAB tasks (e.g. MOT, SOC, PAL, and RTI) as 
cognitive discernable factors between schizophrenia and schizoaffective disorder. They found that the PAL and 
MOT, but not the SOC and RTI, discriminated between the two patient groups, as patients with schizoaffective 
disorder performed better in time on these two cognitive tasks. These results suggest that visuo-spatial explicit 
memory and visuo-motor coordination may be relevant for distinguishing schizophrenia from schizoaffective 
disorder. 
Although encouraging, the results from these studies must be replicated by other research teams before it can be 
concluded that CANTAB is useful for schizophrenia's cognitive profile subtyping. 
3.5. Predictors of schizophrenia 
Studies have been performed to identify behavioral and cognitive predictors of psychosis  [3,67]. These studies 
are important since they may help identify subjects who are psychosis-prone and elaborate programs to prevent 
the development of psychosis. 
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Preliminary evidence suggests that CANTAB may be a useful tool to identify cognitive dysfunctions predicting 
psychosis prior to its apparition. For instance, Wood et al. [67] have investigated whether working memory and 
executive functions as tested with the SWM and DMS tasks were impaired in young people at ultrahigh risk of 
developing psychosis. Both SWM and DMS performance was poorer in the ultrahigh risk subjects relative to 
controls. A non-significant trend emerged towards poorer cognitive performance among subjects who later 
became psychotic compared to those who did not. Those findings suggest that CANTAB could be used as a 
predictive tool to detect subjects at risk of developing psychosis. Similarly, Bartok et al. [7] have investigated 
memory and attention in young adults at the prodromal stage of psychosis, using the PAL, SRM, RVP, and 
SWM tasks. They observed deficits on all tasks in the pre-psychotic patients, relative to healthy controls. Further 
studies to validate the use of CANTAB as a predictive tool for early detection of individuals at risk of 
developing psychosis are warranted. 
3.6. Community functioning 
Since neuropsychological tests do not reflect real-life situations, concerns have been raised about their ecological 
validity. CANTAB faces the same problem as traditional neuropsychological tests. To address this problem, 
Prouteau et al. [48] have used CANTAB to explore the pattern of associations between visuo-spatial cognition 
and community functioning in schizophrenia outpatients participating in a rehabilitation program (15-16 month 
follow-up). CANTAB MOT, PAL, RTI, RVP, and SOC were administered, and community functioning was 
measured with the Multinomah Community Ability Scale (assessed on baseline and endpoint). Using multiple 
regression analyses, they found that a better sustained attention performance was associated with better global 
community functioning at baseline. In a subsequent study involving the same participants, Prouteau et al. [49] 
were further able to show that better baseline visual memory (PAL) predicted better community functioning at 
endpoint (e.g. greater daily living autonomy and greater social competence). Moreover, baseline sustained 
attention performance (RVP) predicted improvements in behavioral problems (e.g. medication compliance) and 
social competence. Planning abilities (SOC) also predicted improvements in social competence. 
The same group [50] also explored the pattern of associations between self-assessed and objective 
neuropsychological performance, using CANTAB and the Subjective Scale to Investigate Cognition in 
Schizophrenia (SSTICS). They found an association between higher subjective complaints and poorer CANTAB 
explicit visual memory (PAL) and planning (SOC) performances. Potvin et al. [45] found similar associations in 
dual diagnosis patients, using the PAL and the SSTICS. 
Overall, the fact that cognition, as measured with CANTAB, predicted psychosocial functioning is consistent 
with the results obtained in studies using traditional neuropsychological tests [18]. Further studies are needed to 
validate the use of CANTAB to identify cognitive predictors of social functioning. 
3.7. Relationships between cognitive and occulomotor functions 
Schizophrenia is associated with subtle occulomotor deficits, which are positively correlated with cognitive 
impairments, mostly frontal lobe deficits [21,22]. Although the topic has not been systematically investigated, a 
few studies have explored the relationships between occulomotor and cognitive deficits in schizophrenia using 
CANTAB. For instance, Hutton et al. [22] investigated the likelihood of smaller (hypometric) saccades in first-
episode schizophrenia patients (relative to controls), and whether hypometria would mirror spatial memory 
impairments (using SSP, SWM SRM, and PRM tasks). They found that schizophrenia patients (both drug-naive 
and treated) made hypometric saccades, relative to healthy controls. In addition, they found that primary saccade 
correlated with SRM, PRM, and SMW scores. 
Hutton and Huddy [21] investigated, in first-episode schizophrenia patients, the relationships between cognitive 
impairments (measured with the SSP, PRM, SWM, SOC, and IED tasks) and occulomotor deficits measured 
using smooth pursuit and antisaccade performance tasks. The authors found deficits in smooth pursuit and 
antisaccade performance in patients, relative to controls. Also, they noticed a correlation between antisaccade 
errors and spatial working memory performance, but no correlation between smooth pursuit velocity and 
cognition. Based on this finding, the authors proposed that spatial working memory and antisaccade performance 
may share the same prefrontal pathways in schizophrenia. 
Although preliminary, the relationships described in these studies between occulomotor and cognitive deficits in 
schizophrenia are consistent with the results of studies using traditional neuropsychological tests [29]. 
In a related domain, it must be noted that Pantelis et al. [44] studied the relationships between negative 
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symptoms, orofacial tardive dyskinesia (OTD) and memory and executive functions. Using a components 
analysis, they found that OTD and negative symptoms were independently associated with spatial working 
memory deficits in schizophrenia. 
3.8. Schizophrenia vs. other disorders and acquired pathology 
CANTAB has been used in many papers to compare the cognitive impairments of schizophrenia to those of other 
patient groups. Allowing a description of the distinctive cognitive deficits of schizophrenia, these studies have 
also an obvious pathophysiological underlying relevance. 
Using the IED task, Pantelis et al. [42] evaluated patients suffering from schizophrenia (chronic), patients with 
frontal lobe lesion, and a control group. By means of a component analysis of the Wisconsin Card Sorting Test 
(WCST), the IED task has been designed and it comprises two types of set-shifts: (i) "intra-dimensional shifts 
(IDS), which involve the transfer of a rule within the same stimulus dimension (e.g. choosing circles instead of 
squares); and (ii) extra-dimensional shifts (EDS), which require a transfer of attention across different stimulus 
dimensions (e.g. choosing on the basis of color rather than the previous category of shape)" [42]. Compared to 
controls and frontal lobe lesion patients, schizophrenia patients had a poorer performance at the intra-
dimensional shift stage of learning, suggesting a failure of inhibitory mechanisms. At the extra-dimensional shift 
stage, schizophrenia patients with prominent negative symptoms exhibited comparable deficits to the frontal lobe 
lesion group. These results were interpreted by the authors as being consistent with the notion of separate 
pathophysiological mechanisms in schizophrenia, involving separate fronto-striatal systems [55]. 
Using the MOT, SSP, WSM, and SOC tasks, Pantelis et al. [43] have assessed spatial working memory, spatial 
span, motor speed and planning abilities in patients with chronic schizophrenia, normal subjects and patients 
with neurological disorders (frontal lobe, temporal lobe and amygdalo-hippocampal lesions, PD). The results of 
this study are indicative of an overall deficit of executive functioning in schizophrenia, even greater than that 
seen in patients with frontal lobe lesions. In addition, the pattern of results (deficits in SWM and SOC) in 
schizophrenia resembled that seen in patients with lesions of the frontal lobe or with basal ganglia dysfunction 
and, to a lesser extent, similar to those found in patients with PD. In contrast, there were no similarities on any of 
the administered tests between the performance of the patients with schizophrenia and that of patients with focal 
temporal lobe lesions. These results provide support to the notion of disturbances in fronto-striatal circuits in 
schizophrenia. 
Using numerous CANTAB tasks (e.g. IED, DMS, PRM, SRM, PAL, SSP, and SWM), Gabrovska-Johnson et al. 
[16] attempted to characterize the neuropsychological deficits in elderly schizophrenia patients and distinguish 
them from those in Alzheimer's disease (AD) and to establish the presence of underlying structural brain 
abnormalities using functional magnetic resonance imaging (fMRI). They found that schizophrenia patients were 
more impaired on most visuo-spatial tasks than AD patients but less impaired on corresponding verbal tasks, 
despite similar overall cognitive impairment. Moreover, the MR scans revealed a correlation between impaired 
performance on visuo-spatial tasks and right-sided enlargement of ventral cerebrospinal fluid (CSF) spaces in the 
schizophrenia patients. 
Using a wide range of cognitive tests, including the CANTAB SOC task, Mcintosh et al. [35] examined whether 
cognitive abnormalities are related to a genetic liability to schizophrenia. Patients suffering from schizophrenia 
and bipolar disorder performed worse on the SOC than controls. Unaffected relatives from "schizophrenia" and 
"mixed bipolar disorder" families also performed on the task. However, these differences did not remain 
significant after adjustment for intellectual function. 
Badcock et al. [3] have examined the specificity of the spatial working memory impairments by comparing the 
mnemonic and executive aspects of working memory performance in schizophrenia and bipolar disorder with 
psychotic features. Both patient groups were impaired relative to the control group on the spatial span task; 
which requires the maintenance and retrieval of stored information. In contrast, only schizophrenia patients 
showed a significant deficit on a SWM sub-score (e.g. "between search errors"), which requires both 
maintenance and manipulation of information in working memory. That is, schizophrenia patients exhibited 
deficits in both short-term memory and executive functions, whereas bipolar I patients displayed only mnemonic 
dysfunctions. Based on this finding, the authors evoked a possible common disturbance in fronto-parietal 
circuitry in the two disorders together with a specific disturbance of fronto-striatal circuitry in schizophrenia. 
In the study of Elliott et al. [11], patients with unipolar depression showed similar deficits to those observed in 
schizophrenia patients when tested with DMS but not with IED or the SOC. Again, these results are consistent 
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with the findings of both mnemonic and executive dysfunctions in schizophrenia. 
Studies comparing schizophrenia patients to other patient groups using CANTAB have consistently highlighted 
deficits in executive functions, coherent with fronto-striatal dysfunctions in the disorder. Functional brain 
imaging studies are required to corroborate this pathophysiological assumption. 
3.9. Pharmacological treatment 
The study of the impact of treatment on cognition in schizophrenia is of importance since cognitive deficits seem 
to predict psychosocial functioning, as mentioned previously. By improving cognition, a better psychosocial 
functioning may be expected. Also highlighting the importance of treatment, two studies have used CANTAB 
and showed a relationship between duration of untreated psychosis (DUP) and cognitive performance (see Table 
5). 
More work is needed before a firm conclusion can be reached about the use of CANTAB to measure cognition in 
pharmacological studies in schizophrenia. Although, Measurement and Treatment Research to Improve 
Cognition in Schizophrenia (MATRICS) was developed in order to provide a consensus about neurocognitive 
tests to be used in schizophrenia and the design of pharmacological trials in this field [19], further studies 
validating the use of CANTAB in this vein are recommended. Future studies will need to determine the time 
span between assessments required to avoid practice effects. A direct comparison between clinical and parallel 
versions is also needed. 
4. Quantitative systematic review method 
In order to present a more systematic review, we tried to consider quantifying the data and thus offer a meta-
analysis of CANTAB findings in schizophrenia. This initiative is described but is too premature in terms of 
results. Searches using electronic search engines, and CANTAB website's bibliographic list were carried out 
(http://www.cantab.com/cantab/ site/home.acds?context= 1306318&instanceid= 1306319) with the following 
key words: "schizophrenia" AND "CANTAB OR Cambridge Neuropsychological Test Automated Battery". 
Controlling for the quality of studies, we have included all papers presenting original data of patients suffering 
from schizophrenia-spectrum disorder compared to healthy volunteers (control), and being tested for cognitive 
function with CANTAB. A total of 12 cross-sectional studies matched our criteria. 
Consistently available test scores across studies were SOC, IED, SSP, DMS, PRM, SWM, and SRM. The 
number of papers reporting all subscales to a test were limited. As reported by Strauss et al. [63], those tests have 
adequate, marginal or low magnitude on test-retest coefficient (e.g. IED, SOC, and SRM, respectively) with the 
exception of PRM, and sometimes subscales of the test evaluation on this coefficient are not there (e.g. SWM-
strategy). Yet, in this quantitative approach to cross-sectional studies, the test-retest qualities of the scales remain 
simply a weakness to the tests and not to the meta-analytic investigation. 
Among studies, the psychopathological assessment had few discrepancies. First, the assessment was 
heterogeneous (e.g. PANSS, SANS or SAPS). Second, not all studies reported symptomatology assessment. 
Moreover, the medication regimen of the patients involved in those studies is not considered consistent. For 
example, few studies report on medication type, or do not report them at all. 
These three factors, limited number of subscales to tests, and lack of knowledge on symptomatology and 
medication regimen of the patients, would render investigation, in the event of heterogeneity, rather difficult. 
Moreover, drawing a conclusion on a set of heterogeneous effect estimate with a limited number of studies 
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Table 5 Summary of pharmacological studies with CANTAB 
Studies Patients Design/procedure Results 
Lawrie et al. 1995 [30] Treatment-resistant and 
treatment-responsive 
schizophrenia 
Functional magnetic resonance 
imaging (fMRI); single photon 
emission tomography (SPECT); 
investigated biological 
abnormalities; controlling for years 
of education 
No broad differences in 
brain-imaging parameters 
between the two groups; 
lower volumes of most brain 
structures in treatment-
resistant patients; treatment-
resistant patients displayed a 
poorer performance on 
overall set of cognitive tasks 
(including CANTAB SRM 
task) 
Barnes et al. 2000 [5] First-episode schizophrenia Examined cognition with CANTAB 
in patients with short and long DUP 
Patients with long DUP 
tended to perform worse on 
an executive attentional set-
shifting task, relative to 
patients with short DUP 
McCartan et al. 2001 [34] Healthy volunteers Measured the impact of 
chlorpromazine and haloperidol on 
LI; measures of frontal lobe 
function were performed with 
CANTAB 
Chlorpromazine enhanced 
LI, whereas haloperidol was 
associated with impaired 
SWM 
Joyce et al. 2002 [26] First-episode schizophrenia Investigated the relationship 
between cognitive (executive 
dysfunction) performance and DUP 
75% of patients were able to 
perform the IED task; 25% 
who failed had significantly 
longer DUP 
Turner et al. 2004 [64] Chronic schizophrenia Double-blind, randomized, placebo-
controlled, crossover study; 
examined the potential cognitive 
enhancing effect of modafinil 
Significant improvements in 
attentional set-shifting; 
trends towards 
improvements in visual 
memory and spatial planning 
abilities 
Chouinard et al. 2005 [9] Schizophrenia Polypharmacy with cognitive 
enhancing agent, rivastigmine; 
cross-over clinical trial; measured 
cognitive performance 
No significant 
improvements in executive 
functions, procedural 
memory (SOC), sustained 
attention (RVP), semantic 
memory (PAL) and working 
memory (SWM) 
Potvin et al. 2006 [47] Schizophrenia-spectrum 
disorder with comorbid SUD 
Impact of quetiapine on cognition; 
12-week open-label trial 
Improvements were noticed 
on the PAL and SWM tasks; 
authors were not able to rule 
out a practice effect 
Pampoulova et al. 2006 
[41] 
Schizophrenia Investigated the potential cognitive 
toxicity of quetiapine prescribed at 
dosage higher than the 
recommended (200-800 mg); for 6 
weeks 
Observed no decline in 
psychomotor speed and 
spatial working memory; 
suggesting a lack of 
cognitive toxicity requires 
revised treatment regimen 




Cognitive dysfunction has been recognized as a primary and enduring core deficit in schizophrenia, rather than 
the previous focus on positive and negative symptoms. Schizophrenia patients have difficulties performing tests 
of attention, working memory, verbal learning and memory, executive functions, language skills, and social 
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cognition. These deficits are linked to many functional domains, including impairments in occupational and 
social behavior. However, the study of cognition in schizophrenia raises practical and methodological concerns, 
which have led researchers to use a broad range of tests and batteries, including CANTAB. Over the last decade, 
this battery has been regularly utilized in cognitive studies in schizophrenia. In this review, we have evaluated 
the strengths and weaknesses of CANTAB for the assessment of cognition in schizophrenia, as the battery is the 
subject of more and more interest. 
The use of a computerized battery presents some methodological and practical advantages over traditional 
neuropsychological tests. The main advantage of CANTAB is the standardization of administration. The 
rigorous experimental heritage of the CANTAB and the wide range of data already collected have allowed 
effects to be related to particular components of cognitive function and to potential underlying neural substrates. 
In the aftermath of these results, neuroimaging studies have been initiated with the promise of a greater 
understanding of the neurobiological bases of neurological and psychiatric disorders. 
Several neuropsychologists and researchers remain skeptical about this new era of computerized testing, mainly 
because of the lack of comparison between traditional neuropsychological tests and these new computerized 
tests, including CANTAB. At the moment, clear guidelines on how to use CANTAB for assessment of change in 
cognitive function are lacking. Thus, CANTAB alone cannot substitute for the traditional neuropsychological 
tests routinely used in clinical settings. In addition, the ecological validity of CANTAB needs to be further 
investigated in order to establish the value of CANTAB tests as predictors of community functioning. 
Furthermore, this battery necessitates methodological improvements, such as standardization with young 
populations. According to Luciana [32], CANTAB is valid in populations ranging from 4 to 90 years of age. 
However, it remains to be shown whether CANTAB is also valid in schizophrenia patients for the same age 
range. 
Despite these shortcomings, the use of CANTAB in schizophrenia has generally corroborated results of 
neuropsychological studies using traditional tests and has allowed an advance in our knowledge about cognition 
in schizophrenia. For instance, CANTAB has enabled researchers to highlight significant deficits affecting broad 
cognitive domains in schizophrenia (e.g. working memory, decision-making, attention, executive functions, and 
visual memory). The cognitive deficits highlighted in schizophrenia with CANTAB are similar to those 
documented using traditional (visuo-spatial) neuropsychological tests (e.g., Tower of London, WCST) [13]. 
This pattern of cognitive impairments in schizophrenia shows great variability from one patient to another. This 
heterogeneity is plausible in light of the symptomatic heterogeneity of schizophrenia. In the last decade, 
important efforts have been invested in providing a more refined description of the phenotypic features of the 
pathology, using neuropsychological tests [27]. From that perspective, CANTAB tasks have been recently used 
to divide schizophrenia patients into distinctive cognitive profiles subgroups, both empirically and clinically 
useful. Thus far, CANTAB has been successfully used to distinguish the cognitive profile of: (i) schizophrenia 
patients with mild (type A) and marked (type B) neurological signs [2]; schizophrenia patients with and without 
substance use disorder [45]; and (iii) patients with schizophrenia versus schizoaffective disorder [62]. In light of 
cognitive remediation, knowledge of differences between cognitive profiles is very important in order to 
facilitate revalidation to particular patients. Although encouraging, these results must be replicated by other 
research teams before it can be concluded that CANTAB is useful for schizophrenia's cognitive profile 
subtyping. 
Preliminary evidence suggests that CANTAB may be a useful tool to identify cognitive dysfunctions predicting 
psychosis. Wood et al. [67] have showed impairments in working memory and executive functions in young 
people at ultrahigh risk of developing psychosis, relative to controls. Similarly, Bartok et al. [7] have described 
overall deficits in memory and attention in young adults at the prodromal stage of psychosis, relative to controls. 
Further studies to validate the use of CANTAB as a predictive tool for early detection of individuals at risk of 
developing psychosis are warranted. 
CANTAB has been successfully used to compare the cognitive profile of schizophrenia patients, relative to the 
cognitive performance of patients with other acquired pathologies, including patients with unipolar depression 
[11], frontal lobe lesions and basal ganglia dysfunctions [43], PD and temporal lobe lesions [43], Alzheimer's 
disease [16], and bipolar disorder [35]. Interestingly, studies comparing schizophrenia patients to other patient 
groups using CANTAB have consistently highlighted deficits in executive functions, coherent with fronto-
striatal dysfunctions in the disorder. Functional brain imaging studies are required to corroborate this 
pathophysiological assumption. 
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Also relevant to the pathophysiology of schizophrenia, preliminary studies have showed positive correlations 
between occulomotor frontal cognitive deficits in schizophrenia, using CANTAB [21,22]. Although preliminary, 
the relationships described in these studies are consistent with the results of studies using traditional 
neuropsychological tests [29]. In addition, these results suggest that cognitive and occulomotor deficits in 
schizophrenia may share common abnormal frontal substrates. 
CANTAB has also been used to explore the associations between visuo-spatial cognition and community 
functioning. Baseline performance in attention and working memory, which are impaired early in schizophrenia, 
predicted improvements in community functioning and behavioral problems, such as medication compliance. In 
addition, planning abilities, which are also disturbed at the onset of the disease, predicted improvements in social 
competence [48,49]. The fact that cognition, as measured with CANTAB, predicted psychosocial functioning is 
consistent with the results obtained in studies using traditional neuropsychological tests [18]. Further studies are 
needed to validate the use of CANTAB to identify cognitive predictors of social functioning. 
As for the use of CANTAB in the evaluation of the impacts of pharmacological agents on cognition in 
schizophrenia, a few promising studies have been conducted so far. However, their validity is questioned by the 
lack of studies comparing the impact of medications on cognition, as measured with traditional 
neuropsychological tests and CANTAB tasks. It remains to be determined if CANTAB is sensitive enough to 
measure the cognitive impact of pharmacological interventions. 
CANTAB comprises "user-friendly" computerized visuo-spatial tasks administered in a standardized way, which 
will require, in the future, to be compared head-to-head to traditional neuropsychological tests. In schizophrenia, 
this battery has been successfully used in cross-sectional studies, which have highlighted a broad range of visuo-
spatial cognitive deficits in schizophrenia, consistent with the results obtained with some traditional 
neuropsychological tests, like the Tower of London and the WCST. However, we must draw prudent 
conclusions in regards to usability of CANTAB in assessment of the whole visuo-spatial cognitive deficit in 
schizophrenia, due to the fact that most of studies reviewed herein tested only a subset of visuo-spatial abilities. 
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